IMRX
SHORT CANDIDATEMeanRevComposite
19.60
Technical
18.70
Fundamental
19.90
Rank
—
Price
4.60
Hurst
0.22
As of
Jun 25, 2026
Daily
Immuneering Corporation
HealthcareBiotechnologyImmuneering Corporation is an oncology-focused company developing cancer treatments for the U.S. market. The company's lead candidate, atebimetinib, is undergoing Phase 3 testing for pancreatic and non-small cell lung tumors with RAS or RAF mutations, while a second program, envometinib, is in earlier-stage trials for solid tumors. Immuneering is also collaborating with major pharmaceutical firms to test its compounds in combination with existing therapies for various lung cancer subtypes.
Market cap
$288.6M
P/E (trailing)
—
P/E (forward)
-3.55
PEG ratio
—
Dividend yield
—
Beta
0.39
52w range
3.86 – 10.08
Return on equity
-52.15%
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 4.45 (-50.6%) · range 3.92–9.26
Cycle position
14/ 100 cycle scoreENTRY ZONE
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 81 · STRONG SETUP · exit proximity 0
Conviction
41/ 100 · maturity 0%
Buildup.337
EMA entry setup.4281
Fundamentals.2520
Volume profile
POC
5.16
Price vs POC
-13.8%
Overhead supply
80%
Runway
+1.0%
Value area 4.41–5.68 · 80% of 120d volume overhead · heavy supply
Contributing sources
No source detections in the last 21 days.
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -16.24% | +9.51% | mature |
| 40d | +3.17% | +9.51% | mature |